Showing results (71-80 of 104) with videos related to
Sort By:
Pageof 11
The British Journal of Dermatology|March 15, 2012
Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective studyM Viguier, C Pagès, F Aubin, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 18, 2015
Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis surveyP C M van de Kerkhof, K Reich, A Kavanaugh, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|July 26, 2014
Development and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and cliniciansH Gilet, A Roborel de Climens, B Arnould, et al.Journal of Autoimmunity|March 14, 1998
Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4H Bachelez, B Flageul, L Dubertret, et al.The British Journal of Dermatology|October 15, 2021
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasisK B Gordon, M Lebwohl, K A Papp, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 6, 2018
Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015L Polivka, N Oubaya, H Bachelez, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 19, 2020
Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre studyM-A Richard, C Paul, G De Pouvourville, et al.The British Journal of Dermatology|June 11, 2017
Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasisK A Papp, H Bachelez, A Blauvelt, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 22, 2016
Predictors of long-term drug survival for infliximab in psoriasisQ Magis, D Jullien, C Gaudy-Marqueste, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 2, 2022
Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohortF Assan, B Husson, S Hegazy, et al.Pageof 11